Recently, four cardiovascular outcome trials (CVOTs) have been conducted to explore the safety and efficacy of SGLT2 inhibitors on cardiovascular outcomes in T2DM patients with a high risk of cardiovascular events (EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS, and VERTIS-CV) (15–18). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.